• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Expression of urokinase-type plasminogen activator and plasminogen activator inhibitor in colon disease.

作者信息

Miseljic S, Galandiuk S, Myers S D, Wittliff J L

机构信息

Department of Biochemistry, University of Louisville, Kentucky.

出版信息

J Clin Lab Anal. 1995;9(6):413-7. doi: 10.1002/jcla.1860090613.

DOI:10.1002/jcla.1860090613
PMID:8587011
Abstract

Surveillance colonoscopy and biopsy are inaccurate methods of predicting the likelihood of ulcerative colitis patients to develop colon carcinoma. We examined uPA and PAI-1 as potential markers for assessing these patients and those with familial polyposis who are at risk of developing colon cancer. For comparison, biopsies of normal colon and Crohn's disease were evaluated. We examined 77 colonic mucosa specimens taken from patients undergoing elective resection for benign and malignant colonic disease. uPA and PAI-1 were measured using a monoclonal antibody-based ELISA kit (American Diagnostica, Greenwich, CT) and expressed as ng/mg extract protein. Intra- and interassay controls of uPA gave CV = 3-4% and CV = 8-9%, respectively, while those for PAI-1 were 6-7% and 10-11%, respectively. The Mann-Whitney test showed that both uPA and PAI-1 expression were significantly higher in colon cancer, chronic ulcerative colitis, and Crohn's disease than in normal colon. uPA in familial polyposis samples was similar to that of normal colon, while PAI-1 was much lower than in normal colon. Neither patient age nor sex appeared to influence the expression of these potential markers in any tissue. The pattern of uPA and PAI-1 expression in normal, benign and malignant colon suggests these proteins deserve further consideration as markers for assessing colon carcinoma risk.

摘要

相似文献

1
Expression of urokinase-type plasminogen activator and plasminogen activator inhibitor in colon disease.
J Clin Lab Anal. 1995;9(6):413-7. doi: 10.1002/jcla.1860090613.
2
Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer.尿激酶型纤溶酶原激活剂和基质金属蛋白酶在人结直肠癌中的活性与表达
BMC Cancer. 2006 Aug 18;6:211. doi: 10.1186/1471-2407-6-211.
3
Urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) in tissue and serum of head and neck squamous cell carcinoma patients.头颈部鳞状细胞癌患者组织和血清中的尿激酶型纤溶酶原激活物(uPA)和纤溶酶原激活物抑制剂1型(PAI-1)
Eur J Cancer. 1998 Jul;34(8):1193-7. doi: 10.1016/s0959-8049(98)00029-x.
4
External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts.欧洲范围内多中心对人乳腺癌组织提取物中尿激酶型纤溶酶原激活剂(uPA)及其1型抑制剂(PAI-1)进行抗原测定(酶联免疫吸附测定)的外部质量评估。
Br J Cancer. 1998 Dec;78(11):1434-41. doi: 10.1038/bjc.1998.704.
5
Urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 and type 2 in stage I malignant melanoma.I期恶性黑色素瘤中的尿激酶型纤溶酶原激活物及1型和2型纤溶酶原激活物抑制剂
Oncol Rep. 2003 May-Jun;10(3):635-9.
6
Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.用于测定乳腺癌患者原发肿瘤组织中尿激酶型纤溶酶原激活剂和纤溶酶原激活剂抑制剂1 mRNA的定量逆转录聚合酶链反应检测:与酶联免疫吸附测定法进行抗原定量的比较
Int J Mol Med. 2008 Feb;21(2):251-9.
7
Significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 (PAI-1) expression in human colorectal carcinomas.尿激酶型纤溶酶原激活物及纤溶酶原激活物抑制剂-1(PAI-1)在人大肠癌中的表达意义
Tumour Biol. 2002 May-Jun;23(3):170-8. doi: 10.1159/000064033.
8
Expression and prognostic significance of urokinase and plasminogen activator inhibitor type-1 in endometrial hyperplasia and cancer.尿激酶及1型纤溶酶原激活物抑制剂在子宫内膜增生及癌中的表达及预后意义
J Exp Clin Cancer Res. 2001 Jun;20(2):239-46.
9
High level of urokinase-type plasminogen activator is a new prognostic marker in patients with gastric carcinoma.高水平的尿激酶型纤溶酶原激活剂是胃癌患者新的预后标志物。
Cancer. 1997 Mar 1;79(5):878-83.
10
Expression of hormone receptors, cathepsin D, and HER-2/neu oncoprotein in normal colon and colonic disease.激素受体、组织蛋白酶D和HER-2/neu癌蛋白在正常结肠及结肠疾病中的表达
Arch Surg. 1993 Jun;128(6):637-42. doi: 10.1001/archsurg.1993.01420180035007.

引用本文的文献

1
Nutrient starvation activates ECM remodeling gene enhancers associated with inflammatory bowel disease risk in fibroblasts.营养饥饿会激活成纤维细胞中与炎症性肠病风险相关的细胞外基质重塑基因增强子。
bioRxiv. 2024 Sep 12:2024.09.06.611754. doi: 10.1101/2024.09.06.611754.
2
Urokinase-type plasminogen activator blockade ameliorates experimental colitis in mice.尿激酶型纤溶酶原激活物阻滞剂可改善实验性结肠炎小鼠的病情。
Sci Rep. 2023 Feb 18;13(1):2899. doi: 10.1038/s41598-023-29824-1.
3
Relationships of protein biomarkers of the urokinase plasminogen activator system with expression of their cognate genes in primary breast carcinomas.
尿激酶纤溶酶原激活系统蛋白生物标志物与原发性乳腺癌中相应基因表达的关系。
J Clin Lab Anal. 2019 Nov;33(9):e22982. doi: 10.1002/jcla.22982. Epub 2019 Jul 29.
4
Ly49E expression on CD8αα-expressing intestinal intraepithelial lymphocytes plays no detectable role in the development and progression of experimentally induced inflammatory bowel diseases.CD8αα 表达的肠道上皮内淋巴细胞上的 Ly49E 表达在实验性诱导的炎症性肠病的发展和进展中没有可检测到的作用。
PLoS One. 2014 Oct 13;9(10):e110015. doi: 10.1371/journal.pone.0110015. eCollection 2014.
5
The plasminogen activator inhibitor system in colon cancer cell lines is influenced by the CO2 pneumoperitoneum.CO2 气腹对结肠癌细胞系纤溶酶原激活物抑制剂系统的影响
Int J Colorectal Dis. 2011 Jan;26(1):37-43. doi: 10.1007/s00384-010-1062-y. Epub 2010 Oct 8.
6
Expression of urokinase-type plasminogen activator and its receptor in gastric fibroblasts and effects of nonsteroidal antiinflammatory drugs and prostaglandin.尿激酶型纤溶酶原激活剂及其受体在胃成纤维细胞中的表达以及非甾体抗炎药和前列腺素的作用
Dig Dis Sci. 2003 Dec;48(12):2247-56. doi: 10.1023/b:ddas.0000007859.10680.b1.